Sutro Biopharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Sutro Biopharma generated cash of -$111,616,000, which is less than the previous year. Cash used in financing activities reached the amount of $137,554,000 last year. Net change in cash is therefore $22,014,000.
Cash Flow
| 2016 | -13.15M | 9.59M | 177K |
|---|---|---|---|
| 2017 | -37.07M | 32.60M | 14.63M |
| 2018 | 12.68M | -80.19M | 170.78M |
| 2019 | -65.02M | -51.13M | -4.18M |
| 2020 | -67.80M | 604K | 269.24M |
| 2021 | -81.67M | -97.31M | 3.25M |
| 2022 | 3.54M | -35.02M | 48.31M |
| 2023 | -111.61M | -3.92M | 137.55M |
STRO Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 48.12M | 31.28M | 207.02M | 4.97M | 125.31M | 22.03M | 11.86M | 15.25M |
Operating activities | ||||||||
Net income | -106.79M | -119.20M | -105.53M | -32.12M | -55.74M | -35.31M | -19.68M | 1.70M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 6.81M | 5.69M | 4.84M | 4.29M | 4.77M | 4.53M | 4.99M | 5.66M |
Stock-based compensation expense | 24.90M | 26.30M | 23.24M | 11.91M | 10.31M | 0 | 1.39M | 968K |
| Deferred income tax benefit | 24.90M | 26.30M | 23.24M | 11.91M | 10.31M | 0 | 1.39M | 968K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | -28.95M | 5.34M | -6.89M | 739K | -3.80M | -865K | -1.04M | -171K |
Inventories | 0 | 0 | -4.54M | -58K | -1.25M | -1.66M | -354K | -389K |
Accounts payable | 4.81M | -1.22M | 6.43M | -947K | 2.25M | 209K | -473K | 874K |
Cash generated by operating activities | -111.61M | 3.54M | -81.67M | -67.80M | -65.02M | 12.68M | -37.07M | -13.15M |
Investing activities | ||||||||
Purchases Of Investments | -460.30M | -216.67M | -248.72M | -130.74M | -196.22M | -81.46M | -14.22M | -52.30M |
Investments In Property Plant And Equipment | -4.31M | -7.85M | -15.32M | -7.12M | -3.48M | -1.55M | -3.31M | -4.39M |
Acquisitions Net | 0 | 28.73M | 0 | 0 | 47.65M | 0 | 0 | 0 |
Cash generated by investing activities | -3.92M | -35.02M | -97.31M | 604K | -51.13M | -80.19M | 32.60M | 9.59M |
Financing activities | ||||||||
Common Stock Issued | 11.97M | 56.27M | 4.25M | 251.41M | 0 | 84.43M | -191K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -7K | -314K | -327K | 0 | 0 | 0 |
Repayments of term debt | -12.5M | -9.37M | 0 | -10M | -5M | 0 | 15M | 0 |
Cash used in financing activities | 137.55M | 48.31M | 3.25M | 269.24M | -4.18M | 170.78M | 14.63M | 177K |
Net Change In Cash | 22.01M | 16.84M | -175.73M | 202.04M | -120.33M | 103.27M | 10.16M | -3.38M |
Cash at end of period | 70.14M | 48.12M | 31.28M | 207.02M | 4.97M | 125.31M | 22.03M | 11.86M |
| Data source | Data source | Data source | Data source | Data source | Data source |